MTManami Takahashi

Manami Takahashi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Manami Takahashi has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Successful Control of Langer hans Cell Sarcoma in a Super‐Aged Patient Using Intensity‐Modulated Radiotherapy

    by Hiromu Okuguchi, Taku Fujimura, Manami Takahashi‐Watanabe, Emi Yamazaki, Ryo Amagai, Yumi Kambayashi, Yoshihide Asano

  • Three Cases of Advanced Melanoma With Severe irAE Colitis With Rapid Tumor Progression Following Infliximab Administration

    by Emi Yamazaki, Taku Fujimura, Yumi Kambayashi, Manami Takahashi‐Watanabe, Kenta Oka, Erika Tamabuchi, Yusuke Muto, Akira Hashimoto, Yoshihide Asano

    Immune checkpoint inhibitors (ICIs) have improved melanoma outcomes but can cause severe immune‐related colitis. Infliximab is often used for steroid‐refractory cases, yet its effect on tumor control remains uncertain. We describe three advanced melanoma patients who developed grade 3–4 colitis after nivolumab plus ipilimumab and were treated with infliximab. Although gastrointestinal symptoms improved, all showed rapid disease progression and died within 3–9 months. These cases suggest that infliximab may compromise antitumor immunity in melanoma patients receiving ICIs.


  • Two cases of advanced melanoma with BRAF L597 mutation: Options for systemic treatment

    by Ryo Amagai, Taku Fujimura, Yumi Kambayashi, Manami Takahashi‐Watanabe, Emi Yamazaki, Erika Tamabuchi, Kenta Oka, Yusuke Muto, Akira Hashimoto, Yoshihide Asano

    The combination of BRAF and MEK kinase inhibitors is a well‐established treatment for BRAF V600‐mutated advanced melanoma. However, the efficacy of these therapies against less common BRAF mutations, such as BRAF L597, remains unclear. We report two cases of advanced melanoma harboring the BRAF L597 mutation. In the first case, a 77‐year‐old man with metastatic melanoma achieved complete remission following combination therapy with nivolumab and ipilimumab. In the second case, a 50‐year‐old woman with metastatic melanoma exhibited resistance to multiple systemic therapies, including nivolumab, ipilimumab, and targeted therapy with encorafenib and binimetinib. These cases highlight the variable therapeutic responses in melanoma with the BRAF L597 mutation, suggesting that immune checkpoint inhibitors may be a viable first‐line treatment, particularly for patients with a high tumor mutational burden. Further studies are needed to establish optimal treatment strategies for this rare mutation.


  • Open Access

    Comprehensive Analysis of the Chemokine/Cytokine Profiles in Advanced Mycosis Fungoides and Atopic Dermatitis

    by Manami Takahashi-Watanabe, Taku Fujimura, Emi Yamazaki, Ryo Amagai, Kenta Oka, Yumi Kambayashi, Maki Ozawa, Tomoko Chiba, Mayuko Onodera-Amagai, Toshiya Takahashi, et al.

    Mycosis fungoides (MF) is an indolent form of cutaneous T‐cell lymphoma. Its early lesions are important to be distinguished from atopic dermatitis (AD) because of their similar immune microenvironment. We have previously demonstrated that several chemokines are involved in the pathogenesis of advanced MF. Therefore, we sought to comprehensively analyze the changes in the immune environment during the advanced phase of MF by focusing on serum cytokines and chemokines and to identify potential biomarkers for the early detection of the transition to the advanced phase of MF. Sera from 11 cases of advanced‐stage MF, 16 cases of mild AD (median EASI score = 5.75), 16 cases of severe AD (median EASI score = 28.1), and 21 healthy volunteers were analyzed using the Bio‐Plex 40 multiplex immunoassay system. The results revealed significant increases in immunosuppressive macrophage‐related factors (IL‐4, MIF, CCL3) in MF patients compared to those with AD and healthy controls. In contrast, IL‐2, CCL1, CCL7, CCL21, CCL25, and CCL26 were significantly increased in severe AD patients compared to MF patients and healthy controls. Our findings suggest that several chemokines and cytokines contribute to an immunosuppressive environment favorable for tumor growth, distinguishing MF from AD. Moreover, T‐cell proliferation and migration factors, which are mainly involved in maintaining inflammation, are elevated in severe AD compared to MF. In addition to elucidating the differences in the pathogenesis of these diseases, these factors may be important in the differential diagnosis of early MF and AD. Further studies are warranted to confirm these findings.


  • Open Access

    Spontaneous Coronary Artery Dissection at 3 Years After Vertebral Artery Dissection Without Relationship to Pregnancy

    by Yutaka Yoshino, Hiroyuki Takaoka, Hiromichi Oishi, Shuhei Aoki, Hiroki Goto, Manami Takahashi, Satomi Yashima, Noriko Suzuki-Eguchi, Haruka Sasaki, Makiko Kinoshita, et al.

    Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.

  • Open Access

    Neurodegenerative processes accelerated by protein malnutrition and decelerated by essential amino acids in a tauopathy mouse model

    by Hideaki Sato, Yuhei Takado, Sakiko Toyoda, Masako Tsukamoto-Yasui, Keiichiro Minatohara, Hiroyuki Takuwa, Takuya Urushihata, Manami Takahashi, Masafumi Shimojo, Maiko Ono, et al.

    Intake of specific seven essential amino acids affects the pathology of the brain.


  • Open Access

    Tau‐induced brain atrophy and neuroinflammation accelerated by low‐protein diet and decelerated by selected essential amino acids in a murine model of tauopathies

    by Yuhei Takado, Hideaki Sato, Masako Tsukamoto‐Yasui, Keiichiro Minatohara, Manami Takahashi, Takuya Urushihata, Hiroyuki Takuwa, Maiko Ono, Jun Maeda, Naruhiko Sahara, et al.

    Background: Nutritional epidemiology has implicated dietary protein intake in senile dementias. However, mechanistic links of protein and amino acids to age‐related neurodegenerative conditions remain unclear. Here, we tested the hypothesis that dietary intake of protein and amino acids could affect neuronal functions and survival in a mouse model of tauopathies, which develops tau pathologies leading to progressive brain atrophy with aging.Methods: Non‐transgenic (nTg) and tauopathy model (rTg4510) mice were fed a normal protein diet (NPD) or low protein diet (LPD) from 3 months of age, and brain volume and tau pathologies were measured at 6.5 months of age by MRI and PET, respectively. These imaging assays were also applied to NPD‐ and LPD‐fed mice treated with essential amino acids (EAAs), seven essential amino acids (EAAs), which are primarily composed of leucine, phenylalanine, and lysine with high fluxes into the brain and contain minimum levels of tryptophan, an origin of inflammation‐related kynurenine pathways. Moreover, we performed gene expression profiling of the cortical tissues collected from these mice.Results: LPD profoundly accelerated the brain atrophy in rTg4510 mice relative to NPD. EAA supplementation to rTg4510 mice markedly suppressed cortical volume reductions in both LPD‐ and NPD‐fed rTg4510. LPD and EAA did not overtly alter PET‐detectable tau depositions uncorrected for atrophy‐induced partial volume effects, raising a possibility of decreased tau burdens in each of surviving neurons to some extent. Gene expression profiling demonstrated neuroinflammatory changes and neuronal dysfunctions in rTg4510 mice, which were worsened by LPD and attenuated by EAAs. Notably, kynurenine levels were elevated by LPD, and this alteration was reversed by EEAs, presumably by competition between EEAs and kynurenine on the entry into the brain.Conclusion: Our findings highlight the critical roles of specific EEAs in the protection of neurons against tau‐induced toxicity and neuroinflammation.


  • Open Access

    Coexistence of Marfan-like Connective Tissue Disease with Morphologic Left Ventricular Non-compaction

    by Satomi Yashima, Hiroyuki Takaoka, Togo Iwahana, Manami Takahashi, Yusuke Kondo, Hideki Ueda, Aya Saito, Yuya Ito, Noboru Motomura, Nobuyuki Hiruta, et al.

    We treated a man with co-incident Marfan-like connective tissue disease with morphologic left ventricular non-compaction (LVNC). He underwent valve-sparing aortic root replacement because of aortic root dilation at 43 years old. Pathological findings of the aorta revealed cystic medio-necrosis, consistent with Marfan syndrome. He developed congestive heart failure caused by LVNC at 47 years old. His daughter had scoliosis, and he had several physical characteristics suggestive of Marfan syndrome. We herein report a rare case of a patient who had Marfan-like connective disease with an LVNC appearance.


  • 3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity

    by Yuta Takamura, Manami Takahashi, Midori Nishii, Osamu Shibahara, Masaki Watanabe, Michiko Fujihara, Hiroki Kakuta